News Quantified

MRUS – merus n.v. - common shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy [Yahoo! Finance]

Merus (NASDAQ: MRUS) had its price target raised by analysts at Citigroup Inc. from $89.00 to $97.00. They now have a "buy" rating on the stock.

Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock.

Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC [Yahoo! Finance]

-0.6%

MISS

-4.2%

BEAT

Needham & Company LLC

Form SCHEDULE 13G Merus N.V. Filed by: COMMODORE CAPITAL LP

Form 8-K Merus N.V. For: Dec 04

Form 8-K Merus N.V. For: Nov 27

Form SC 13G/A Merus N.V. Filed by: COMMODORE CAPITAL LP

Form SC 13G/A Merus N.V. Filed by: SAMLYN CAPITAL, LLC

Top News Gainers

3/12 Merus Announces Financial Results for the Fourth Quarter and Full Year 2019 and Provides Business Update 34.7%

10/25 Merus Announces Presentation and Poster on MCLA-128 and MCLA-129 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 16.3%

1/15 Form 4 Merus N.V. For: Jan 13 Filed by: BVF INC/IL 13.8%

9/19 Merus NV (NASDAQ: MRUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.8%

4/3 Form 4 Merus N.V. For: Apr 01 Filed by: Throsby Mark 9.8%

11/4 Form 6-K Merus N.V. For: Nov 04 7.0%

4/24 Form SC 13G/A Merus N.V. Filed by: EcoR1 Capital, LLC 6.8%

3/19 Merus NV (NASDAQ: MRUS) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 6.3%

8/10 Merus NV (NASDAQ: MRUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.9%

4/16 Form 8-K Merus N.V. For: Apr 15 5.8%

Top News Decliners

10/27 Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions -16.2%

3/18 Merus NV (NASDAQ: MRUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock. -10.8%

3/10 Form 4 Merus N.V. For: Mar 04 Filed by: Throsby Mark -8.1%

4/29 Form 10-K/A Merus N.V. For: Dec 31 -7.5%

8/19 Form 6-K Merus N.V. For: Jun 30 -6.9%

4/30 Form POS AM Merus N.V. -6.6%

3/7 Merus NV (NASDAQ: MRUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $20.00 price target on the stock. -6.2%

5/20 Merus to Present at the RBC Capital Markets 2019 Healthcare Conference -5.9%

10/23 Merus NV (NASDAQ: MRUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.3%

4/6 Form 4 Merus N.V. For: Apr 02 Filed by: Throsby Mark -4.6%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day